Table 1. Overview of positive biopsy rates in larger published trials of direct and fusion MRI-targeted biopsy of the prostate.

Population	Method	Positive target biopsy
177 men with PI-RADS 3+ targets, most biopsy naïve (24)	Direct	36% (64/177)
106 men with ≈ PI-RADS 4+ targets and prior negative transrectal ultrasound guided biopsy (25)	Direct	37% (39/106)
176 men with ≈PI-RADS 3+ and prior negative transrectal ultrasound guided biopsy (26)	Direct	73% (202/277)
142 biopsy naïve men with PI-RADS 3+ targets (17)	Direct	70% (99/142)
Second subcohort of 25 men with ≈ PI-RADS 4+ targets, most with prior negative transrectal ultrasound guided biopsy (data in this paper)	Direct	84% (21/25)
1,003 men with ≈PI-RADS 3+ targets, most with prior negative transrectal ultrasound guided biopsy (5)	Fusion	47% (469/1003)
104 men with ≈PI-RADS 4+ targets and prior negative transrectal ultrasound guided biopsy (25)	Fusion	39% (41/104)
825 men with ≈PI-RADS 3+ targets, mix of biopsy naïve and prior transrectal ultrasound guided positive and negative (27)	Fusion	53% (434/825)